Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Affimed Ord Shs
(NQ:
AFMD
)
5.500
-0.040 (-0.72%)
Streaming Delayed Price
Updated: 12:55 PM EDT, Jul 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Affimed Ord Shs
< Previous
1
2
3
4
5
6
Next >
Affimed's Lymphoma Candidate Shows 100% Objective Response Rate At Highest Dose
November 22, 2021
Affimed NV (NASDAQ:AFMD) has announced
Via
Benzinga
Why Affimed Stock Is On Fire Today
November 22, 2021
The biotech's early-stage trial results are turning heads on Wall Street today.
Via
The Motley Fool
Why Affirmed Stock Was Up More Than 12% Wednesday
November 17, 2021
Positive trial results regarding the company's pipeline are buoying the stock's price.
Via
The Motley Fool
Mid-Afternoon Market Update: Dow Falls 200 Points; Rockwell Medical Shares Spike Higher
November 17, 2021
Toward the end of trading Wednesday, the Dow traded down 0.58% to 35,930.89 while the NASDAQ fell 0.27% to 15,930.79. The S&P also fell, dropping 0.23% to 4,690.24. The U.S....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Affimed NV (AFMD) Q3 2021 Earnings Call Transcript
November 10, 2021
AFMD earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Recap: Affimed Q3 Earnings
November 10, 2021
Affimed (NASDAQ:AFMD) reported its Q3 earnings results on Wednesday, November 10, 2021 at 08:00 AM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
Affimed Earnings Preview
June 30, 2021
Affimed (NASDAQ:AFMD) announces its next round of earnings this Thursday, July 01. Here is Benzinga's look at Affimed's Q1 earnings report. Net Income, Earnings, And Earnings Per...
Via
Benzinga
Stocks That Hit 52-Week Highs On Friday
April 23, 2021
On Friday morning, 152 companies hit new 52-week highs. Things to Consider: The largest company by market cap to hit a new 52-week high was ASML Holding (NASDAQ:...
Via
Benzinga
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
November 10, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:...
Via
Benzinga
Exposures
COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For October 21, 2021
October 21, 2021
Upgrades For Coterra Energy Inc (NYSE:CTRA), Piper...
Via
Benzinga
Preview: Affimed's Earnings
April 14, 2021
On Thursday, April 15, Affimed (NASDAQ:AFMD) will release its latest earnings report. Check out Benzinga's preview to understand the implications. What Are Earnings, Net...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
September 30, 2021
Upgrades For Cabot Oil & Gas Corp (NYSE:COG),...
Via
Benzinga
Affimed NV (NasdaqGM:AFMD) (AFMD) Q2 2021 Earnings Call Transcript
September 08, 2021
AFMD earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Earnings Scheduled For September 8, 2021
September 08, 2021
Companies Reporting Before The Bell • Nanobiotix (NASDAQ:NBTX) is likely to report earnings for its first quarter. • Waterdrop (NYSE:WDH) is expected to report...
Via
Benzinga
The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod
September 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc...
Via
Benzinga
Exposures
Product Safety
The Week Ahead In Biotech (Sept. 5-11): Focus On Conferences and Clinical Readouts In Another Quiet Week
September 05, 2021
Biotech stocks extended their gains in the week ending Sept. 3, partly aided by the broader market strength. The news flow was fairly light ahead of the Labor Day holiday...
Via
Benzinga
Analyzing Affimed's Unusual Options Activity
July 13, 2021
Shares of Affimed (NASDAQ:AFMD) saw some unusual options activity on Tuesday. Following the unusual option alert, the stock price moved down to $6.77. Sentiment: BEARISH Option...
Via
Benzinga
The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts
July 01, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) Ambrx Biopharma Inc. (NYSE...
Via
Benzinga
Exposures
Product Safety
Earnings Scheduled For July 1, 2021
July 01, 2021
Companies Reporting Before The Bell • Simply Good Foods (NASDAQ:SMPL) is projected to report quarterly earnings at $0.29 per share on revenue of $244.29 million....
Via
Benzinga
The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus
June 27, 2021
Biotech stocks reversed course and closed the week ended June 25 higher, thanks to the positive broader market sentiment. Eli Lilly and Company (NYSE: LLY) stood out among big...
Via
Benzinga
Exposures
Product Safety
Affimed's AFM13 In Combination With NK Cells Show Improved Tumor Recognition, Killing In Preclinical Studies
May 14, 2021
Affimed NV (NASDAQ: AFMD) has announced the publication of in vitro and in vivo research of its lead innate cell engager (ICE), AFM13 (CD16A/CD30), combined...
Via
Benzinga
Could Affimed Be a Millionaire-Maker Stock?
May 14, 2021
This biotech stock has already produced some big returns this year.
Via
The Motley Fool
Why Affimed N.V. Stock Dropped Today
April 15, 2021
The company's latest quarterly update was less than impressive.
Via
The Motley Fool
The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout
April 27, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 26) 10x Genomics, Inc. (NASDAQ...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Earnings Scheduled For April 15, 2021
April 15, 2021
Companies Reporting Before The Bell • Charles Schwab (NYSE:SCHW) is projected to report quarterly earnings at $0.82 per share on revenue of $4.58 billion. •...
Via
Benzinga
The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split
April 15, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 14) 10x Genomics, Inc. (NASDAQ...
Via
Benzinga
Exposures
COVID-19
The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight
April 10, 2021
Contrary to the strength in the broader market, biotech stocks ended the week ending April 9 lower. The weakness partly reflected a preference for risky bets at the expense of...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug
April 13, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 12) 180 Life Sciences Corp. (...
Via
Benzinga
Exposures
Product Safety
Here's Why Shares of Affimed Skyrocketed Today
April 09, 2021
A 100% response rate is impressive, albeit in just four patients.
Via
The Motley Fool
51 Biggest Movers From Friday
April 12, 2021
Gainers Celcuity Inc. (NASDAQ: CELC) shares climbed 50.9% to close at $21.60 on Friday after the company announced a worldwide licensing agreement with Pfizer to develop and...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.